MA-WATERS-CORPORATION
31.3.2022 14:02:14 CEST | Business Wire | Press release
Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system , the most sensitive and compact benchtop tandem mass spec in its class.i
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005189/en/
Waters’ newest high-performance mass spectrometer is up to 15X more sensitive for quantifying negatively ionizing compounds than its predecessorii and is 45% smaller and uses up to 50% less electricity and gas supply than other high-performance tandem quadrupole mass spectrometers available on the market.iii The Xevo TQ Absolute is designed to help pharmaceutical, food and beverage, and environmental analytical laboratories meet regulations requiring trace-level quantitative mass spectrometry analyses for a broad set of applications.
“The Xevo TQ Absolute is for laboratories looking for industry-leading quantitative sensitivity, accuracy, reproducibility, efficiency and sustainability,” said Jon Pratt, Waters Division Senior Vice President, Waters Corporation. “It offers more analytical firepower in a much smaller footprint than any other mass spec in its class, reaches exceptionally low limits of quantitation, and aids laboratory managers to best optimize their equipment utilization and analytical output.”
For optimal performance, Waters pairs the Xevo TQ Absolute mass spectrometer with Waters’ ACQUITY™ Premier UPLC System with MaxPeak™ HPS technology which eliminates non-specific adsorption of compounds containing phosphate and/or carboxylate groups and improves their recovery. Together, this integrated LC-MS/MS system is designed to drive the limits of quantitation to exceptionally low levels for many applications including:
- Quantifying regulated impurities in drug products
- Performing oligonucleotide bioanalytical assays
- Measuring concentrations of endogenous metabolites in large cohort clinical studies
- Quantifying residues and contaminants in food and environmental samples
- Measuring low-level drugs and toxicants in physiological matrices
- Detecting trace-level leachables from food packaging
The Xevo TQ Absolute incorporates thoughtful design features that enable consistent and reproducible analyses, allowing labs to maintain performance and uptime for longer periods in between routine cleaning and service intervals. This is achieved with new guidance on optimal probe positioning for both sensitivity and robustness and a source shield that helps minimize source contamination by the sample matrix or mobile phase salts.
The Xevo TQ Absolute is optimized for use with the waters_connect™ software platform and is also compatible with Waters MassLynx™ mass spectrometry software. For laboratories painstakingly reviewing the results from large numbers of samples, or those quantifying hundreds of small molecule components and contaminants in a single run, the MS Quan app on waters_connect and its unique Exception Focused Review (XFR) functionality, lets scientists review data in up to half the time it used to take themiv .
Worldwide customer shipments of the Xevo TQ Absolute are expected to commence in May.
Additional Resources
- Register here for our April 7 launch event
- Learn more about the Xevo TQ Absolute features and benefits
- Read the blog post Can Ever-Increasing Analytical Sensitivity and Sustainability Go Hand-in-Hand?
- Follow and connect with Waters via LinkedIn , Twitter , and Facebook
About Waters Corporation (www.waters.com )
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Xevo, ACQUITY, MaxPeak, MassLynx and waters_connect are trademarks of Waters Corporation.
______________________
i
Based on a comparison of the sensitivity and product specifications of currently available instruments on the market
ii
Waters Xevo TQ- XS
iii
Based on a comparison of product specifications for the Sciex 7500, Sciex 6500, Agilent 6495C and Thermo TSQ Altis
iv
Estimate based on time on task comparison of a batch of pesticides in a food safety analysis
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005189/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom